Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator
Clinical Research in Cardiology · 2024
DOI: 10.1007/s00392-024-02394-6 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Research in Cardiology, 2024. Verfasst von Maura M Zylla und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Medical University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. maura.zylla@med.uni-heidelberg.de. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Anti-Arrhythmia Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Heidelberg.
Abstract (Originalsprache)
Background
Due to suspected pro-arrhythmic effects and increased mortality associated with class-IC antiarrhythmic drugs (AADs) in previous trials, AAD therapy in structural heart disease (SHD) is mainly restricted to amiodarone. In the presence of diagnostic and therapeutic advancements in cardiovascular medicine, it remains unclear if previous studies adequately reflect contemporary patients. In clinical practice, class-IC-AADs are occasionally used in individual cases, particularly in patients with an implantable cardioverter defibrillator (ICD).
Methods
This study retrospectively investigated outcome in ICD-carriers with SHD in whom class-IC-AADs were used as an individualized therapy due to failure, side effects, or unacceptable risk of alternative therapeutic options.
Results
Fifty patients from four tertiary centers were included (median age 48.5 years; 52% female). The most common underlying SHD were dilated (42%) or ischemic cardiomyopathy (26%) (median LVEF = 45%). Indications for AAD were sustained ventricular arrhythmias (VA) (58%), symptomatic premature ventricular contractions (26%), or atrial arrhythmias (16%). Median follow-up was 27.8 months. Freedom from sustained VA was 72%, and freedom from ICD therapy was 80%. In 19 patients (38%), AAD therapy was terminated. The most common reason was insufficient efficacy ( n = 8). Pro-arrhythmia was suspected in three patients. Five patients died during follow-up (10.0%), two of cardiovascular cause (4.0%).
Conclusion
In a multicenter cohort of ICD-carriers with SHD, class-IC-AADs were associated with a low rate of pro-arrhythmic effects or cardiovascular mortality. The majority of patients remained free from sustained VA during a follow-up of > 2 years. Further efforts should be made to evaluate the safety of class-IC-AADs in SHD patients receiving contemporary cardiovascular therapy. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Medical University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. maura.zylla@med.uni-heidelberg.de.
- HCR (Heidelberg Center for Heart Rhythm Disorders), Medical University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. maura.zylla@med.uni-heidelberg.de.
- DZHK (German Center for Cardiovascular Research), Partner Site Heidelberg/Mannheim, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. maura.zylla@med.uni-heidelberg.de.
- Department of Cardiology II (Electrophysiology), University Hospital Münster, Albert-Schweitzer-Straße 33, 48149, Münster, Germany.
- Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20251, Hamburg, Germany.
- DZHK (German Center for Cardiovascular Research), partner site Hamburg/Lübeck/Kiel, Martinistr. 52, 20251, Hamburg, Germany.
Förderung
- Universitätsklinikum Heidelberg
Zitieren
APA
Zylla, M. M., Wolfes, J., Schleberger, R., Lawin, D., Kieser, M., Reinke, F., Eckardt, L., Rillig, A., Stellbrink, C., Thomas, D., Frey, N., & Lugenbiel, P. (2024). Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-024-02394-6
Vancouver
Zylla MM, Wolfes J, Schleberger R, Lawin D, Kieser M, Reinke F, et al. Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator. Clinical Research in Cardiology. 2024. doi:10.1007/s00392-024-02394-6
BibTeX
@article{Zylla2024,
author = {Zylla, Maura M and Wolfes, Julian and Schleberger, Ruben and Lawin, Dennis and Kieser, Meinhard and Reinke, Florian and Eckardt, Lars and Rillig, Andreas and Stellbrink, Christoph and Thomas, Dierk and Frey, Norbert and Lugenbiel, Patrick},
title = {Use of class IC antiarrhythmic drugs in patients with structural heart disease and implantable cardioverter defibrillator},
journal = {Clinical Research in Cardiology},
year = {2024},
doi = {10.1007/s00392-024-02394-6}
}
EUVIMED